Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor.

By Y. Shimizu, Y. Nakatsuru, M. Ichinose, Yoshihisa Takahashi, Haruki Kume, J. Mimura, Y. Fujii‐Kuriyama, T. Ishikawa. Proceedings of the National Academy of Sciences of the United States of America, 2000

660 citations recorded by the source corpus.

Subfields: Cancer Research, Health, Toxicology and Mutagenesis

View Paper: https://www.semanticscholar.org/paper/fbb98c269e8bfc5f66feab54d0494585f574a612

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Moorthy
2. A. Kong
3. Changjiang Xu
4. C. Li
5. D. Carlin
6. Chun Chu

Citations in the corpus

• Polycyclic aromatic hydrocarbons: from metabolism to lung cancer. (2015, background): “Carcinogenicities of PAHs are also lost in AhR knockout mice (Nakatsuru et al., 2004; Shimizu et al., 2000),”
• Induction of phase I, II and III drug metabolism/transport by xenobiotics (2005, background): “…the AhR, in response to PAHs or halogenated aromatic hydrocarbon ligands such as benzo[a]pyrene and 2,3,7,8-tetrachlorodibenzo-p- dioxin (TCDD) or dioxin is well established (Gonzalez and Fernandez-Salguero, 1998; Levine and Perdew, 2001; Li et aL, 1998; Nakajima et aL, 2003; Shimizu et aL, 2000).”
• Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. (2010, background): “Transgenic mouse Mice that lack the aryl hydrocarbon receptor (AhR) did not develop tumours after two subcutaneous injections of 2 mg benzo[a]pyrene/animal whereas 100% of their similarly treated AhR-positive counterparts (AhR or AhR) developed malignant tumours at the injection site that were mainl”